Breast Cancer Therapeutics Market worth over $30.63bn by 2025
Published Date: March 6, 2019 Authors: Sumant Ugalmugle, Rupali Swain
Breast Cancer Therapeutics Market size is set to surpass USD 30.63 billion by 2025, according to a new research study published by Global Market Insights, Inc.
Rising prevalence of breast cancer, launch of numerous diagnostic and screening programs globally and favorable insurance and reimbursement policies will serve as high influential factors for the market growth.
Advancement in technologies for cancer biology, increasing research and development for introduction of novel drugs to treat the disease will stimulate the breast cancer therapeutics market expansion over the coming years. Rising adoption of minimally invasive cancer therapy methods should improve patient compliance.
Moreover, increasing awareness towards disease prevention, early screening and diagnosis will further propel the market progression. However, prohibitive cost associated with breast cancer therapeutics may restrain its acceptance in emerging economies. Compliance to therapy may reduce due to high maintenance treatment price.
Get more details on this report - Request Free Sample PDF
Targeted drug therapy segment in the breast cancer therapeutics market is estimated to witness significant growth of 10.3% by 2025 on account of their structure that is deliberately designed to interact with their target and search for specific molecular targets that are associated with cancer. Growing focus of much anticancer drug development on targeted therapies will drive the demand for these products.
Hormone drugs segment accounted for around USD 3.29 billion in 2018. Features such as affecting the activities of tissues and cells at numerous sites in the body, frequently reaching their targets through bloodstream will fuel the segment growth. Additionally, slowing or stopping the development of hormone-sensitive tumors by interfering with effects of hormones on breast cancer cells or by blocking the body’s capability to produce hormones will offer significant segment expansion.
Browse key industry insights spread across 150 pages with 160 market data tables & 12 figures & charts from the report, “Breast Cancer Therapeutics Market Size By Product (Hormone Drugs, Chemotherapy Drugs, Targeted Drug Therapy), By Distribution Channel (Hospitals, Ambulatory Surgical Centers, Clinics, Ecommerce, Retail Pharmacies), Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2019 – 2025” in detail along with the table of contents:
Retail pharmacies distribution channel is poised to attain a CAGR of 9.7% through 2025. The distribution of breast cancer therapeutics through retail pharmacies has become the most popular medium. In 2018, retail pharmacies held the largest market share and will grow at considerable rate over the forecast timeframe owing to increased number of pharmacies in both developed and developing regions.
U.S. breast cancer therapeutics market is predicted to expand at a CAGR of over 9.1% through 2025 led by the increases access to breast cancer screening, diagnosis and treatment services. In addition, growing usage of therapy drug by patients will foster the regional growth. Rising incidence of disease attributed to the increasing exposure to factors such as use of hormone replacement therapy (HRT), lifestyle related factors such as alcohol consumption, obesity and alteration in family size which stimulates the usage rate of therapeutics over the forecast period.
Japan dominated the Asia Pacific market and was valued around USD 1.28 billion in 2018 due to the increase in awareness programs to spread alertness regarding breast cancer screening, robust economic growth and rising disposable income.
Brazil market is projected to grow at a 10.2% CAGR by 2025. Increased life expectancy among individuals and healthcare facility development are the chief features driving the industry growth in the country.
Some of the companies operating in the market are Roche Diagnostics, Pfizer, AstraZeneca, Novartis, Sanofi, Eisai, and Eli Lily. New product launches, strong product pipeline, geographical expansion, mergers and acquisition will mainly boost the business. Chief industry players will endeavor to strengthen their place in this competitive market by implementation these strategies.